Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: dutton: we are raising our price target to $0.90 per share

Re: dutton: we are raising our price target to $0.90 per share

posted on Dec 11, 2007 05:04PM

Well, judging by their statement it's kind of hard not to blame them based on the untimely reporting of corporate financial events. How do you analyze something 3-6 mos. after the fact.

As we have stated before, the financial revenue information for licenses is not available until Patriot Scientific's quarterly results are released. The financial data for the five licenses granted in the quarter ended November 30, 2007, will not be known until mid January 2008, and the four latest licenses' financial data will not be available until after the release of results for the quarter ended February 28, 2008. It is unfortunate that investors are forced to invest in the dark when it comes to net revenue to Patriot Scientic, from these last nine patent licenses. Speculation regarding a possible settlement and its terms is just that - speculation. A final unknown overhanging is the final decision of the U.S. Patent and Trade Office.

Share
New Message
Please login to post a reply